The Pharma Data

MAY 8, 2021

Sandoz, a Novartis division, today announced progress in the late-stage clinical development program for its proposed biosimilar aflibercept. Sandoz will begin enrolling the first patient in MYLIGHT, a clinical Phase III confirmatory efficacy and safety study, shortly 1. source Link.

Biosimilars 52

Biosimilars Clinical Development Production Government 52

The Pharma Data

NOVEMBER 10, 2020

Growing into a biopharmaceutical company, Innovent has built an integrated platform covering from drug discovery, CMC, clinical development and commercialization. Innovent 2020 Virtual R&D day was successfully held with a lot of attention from domestic and overseas investors. SAN FRANCISCO and SUZHOU, China , Nov.

Biosimilars 52

Biosimilars Clinical Trials International Clinical Development 52

The Pharma Data

SEPTEMBER 29, 2021

The cardiology franchise at Bayer already includes a number of products and several other compounds in various stages of preclinical and clinical development. In fiscal 2020, the Group employed around 100,000 people and had sales of 41.4 The Bayer brand stands for trust, reliability and quality throughout the world.

Clinical Development 52

Clinical Development Disease Clinical Trials Trials 52

The Pharma Data

NOVEMBER 26, 2020

27, 2020 /PRNewswire/ — BioInvent International AB ‘s (publ) (“BioInvent”) (OMXS: BINV) Extraordinary General Meeting (the “EGM”) today resolved to approve the Board of Directors’ resolution on a directed issue of 29,395,311 new shares and 14,697,655 new warrants to CASI Pharmaceuticals Inc.

Clinical Trials 52

Clinical Trials Licensing Licensing International 52

The Pharma Data

MAY 2, 2021

Holzkirchen, May 3, 2021 – Sandoz, a Novartis division, today announced progress in the late-stage clinical development program for its proposed biosimilar aflibercept. Sandoz will begin enrolling the first patient in MYLIGHT, a clinical Phase III confirmatory efficacy and safety study, shortly 1. Sandoz Global Communications.

Biosimilars 40

Biosimilars Clinical Development Production Government 40

The Pharma Data

DECEMBER 21, 2020

Legend will receive $75 million from J&J as a clinical development-based milestone payment, per a 2017 collaboration pact. Cilta-cel also won a Breakthrough Therapy designation in China in August.

Therapies 40

Therapies Licensing Licensing Clinical Development 40

The Pharma Data

OCTOBER 27, 2020

27, 2020 /PRNewswire/ — Mirati Therapeutics, Inc. The offering is expected to close on or about October 30, 2020 , subject to customary closing conditions. Adagrasib is an investigational small molecule and selective KRAS G12C inhibitor in clinical development as a monotherapy and in combinations. SAN DIEGO , Oct.

Small Molecule 52

Small Molecule Immune Response Clinical Development Clinical Trials 52

The Pharma Data

DECEMBER 21, 2020

22, 2020 /PRNewswire/ — Ascentage Pharma (6855.HK), 22, 2020 /PRNewswire/ — Ascentage Pharma (6855.HK), UBX1325 is developed from BM-962, a Bcl-xL inhibiting compound licensed to UNITY by Ascentage Pharma for the treatment of age-related diseases. SUZHOU, China and ROCKVILLE, Md. , SUZHOU, China and ROCKVILLE, Md. ,

Clinical Development 40

Clinical Development Disease Treatment Licensing 40

The Pharma Data

NOVEMBER 4, 2020

5, 2020 /PRNewswire/ — Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that its CD40 targeting antibody mitazalimab will be presented at the World Immunotherapy Congress, November 2-6, 2020. CET on November 5, 2020. and AC101 in clinical development by Shanghai Henlius Biotech Inc.).

Packaging 52

Packaging Clinical Development Disease Drugs 52

The Pharma Data

FEBRUARY 24, 2022

The cardiology franchise at Bayer already includes a number of products and several other compounds in various stages of preclinical and clinical development. In fiscal 2020, the Group employed around 100,000 people and had sales of 41.4 The Bayer brand stands for trust, reliability and quality throughout the world.

Clinical Development 52

Clinical Development Therapies Disease Treatment 52

The Pharma Data

SEPTEMBER 16, 2020

16, 2020 /PRNewswire/ — Amgen (NASDAQ:AMGN) announced today that data from its oncology pipeline in solid tumors will be presented during the European Society of Medical Oncology (ESMO) Virtual Congress 2020, Sept. 19-21, 2020. 20, 2020 , from 2:25 p.m. – 21, 2020 , from 2:25 p.m. – 20, 2020, at?11:00

Clinical Trials 52

Clinical Trials Production Trials Government 52

The Pharma Data

NOVEMBER 30, 2020

Kunwar Shailubhai will host a conference call on Wednesday, 2 December 2020 at 4:15 p.m. Dr. Shailubhai will provide updates on the Company’s proposed move from AIM to the Standard Segment of the Main Market of the London Stock Exchange, ongoing clinical trials, as well as other recent developments in Tiziana Life Sciences.

Science 40

Science Clinical Trials Disease Clinical Development 40

The Pharma Data

OCTOBER 28, 2020

Data provide strong rationale for continued development in Huntington’s and other slowly progressive neurodegenerative diseases, including Alzheimer’s. 29, 2020 (GLOBE NEWSWIRE) — Vaccinex, Inc. ROCHESTER, N.Y.,

Clinical Trials 40

Clinical Trials Treatment Clinical Development Disease 40

The Pharma Data

OCTOBER 26, 2020

27, 2020 /PRNewswire/ — Aridis Pharmaceuticals, Inc. ” Panel: Direct Antivirals and Other Agents Against SARS-CoV2 Virus Date: Wednesday, October 28, 2020 Time: 10:30AM- 11:50AM ET. AR-301 is a fully human IgG1 mAb currently in Phase 3 clinical development targeting gram-positive Staphylococcus aureus ( S.

Pharmaceuticals 52

Pharmaceuticals Virus Hospitals Clinical Trials 52

The Pharma Data

OCTOBER 22, 2020

The closing of the offering is expected to occur on or about October 27, 2020, subject to the satisfaction of customary closing conditions. Iterum Therapeutics is advancing its first compound, sulopenem, a novel penem anti-infective compound, in Phase 3 clinical development with an oral formulation and IV formulation.

Clinical Trials 40

Clinical Trials Pharmaceutical Companies Clinical Development Pharmaceuticals 40

The Pharma Data

NOVEMBER 12, 2020

13, 2020 03:00 UTC. The offering is expected to close on November 17, 2020, subject to customary closing conditions. SOUTH SAN FRANCISCO, Calif.–( –( BUSINESS WIRE )– Five Prime Therapeutics, Inc. The size of the offering was upsized from 5,000,000 shares to 7,200,000 shares.

Clinical Development 40

Clinical Development Marketing Research 40

The Pharma Data

DECEMBER 14, 2020

14, 2020 (GLOBE NEWSWIRE) — TG Therapeutics, Inc. NASDAQ: TGTX), a biopharmaceutical company developing medicines for patients with B-cell mediated diseases (“the Company”), today announced the pricing of an underwritten public offering of 6,320,000 shares of common stock at a public offering price of $43.50 NEW YORK, Dec.

Clinical Trials 40

Clinical Trials Clinical Development Production Trials 40

The Pharma Data

NOVEMBER 5, 2020

5, 2020 /PRNewswire/ — Third quarter 2020 revenues increased 32% to $2.29 Third quarter 2020 EYLEA ® U.S. Third quarter 2020 Dupixent ® global net sales (2) , which are recorded by Sanofi, increased 69% to $1.07 Third quarter 2020 Dupixent ® global net sales (2) , which are recorded by Sanofi, increased 69% to $1.07

Production 52

Production FDA Trials FDA Approval 52

Drug Target Review

OCTOBER 16, 2024

It’s an exciting process—anticipating development risks, predicting outcomes, and aligning these with the greater vision of medical advancement. The true joy comes from navigating these complexities and asking the right questions early on, because these foundational steps are critical to the success of any clinical development process.

Clinical Development 52

Clinical Development Drug Development Therapies Disease 52

The Pharma Data

JANUARY 21, 2021

These presentations will take place as part of the IASLC 2020 World Conference on Lung Cancer (#WCLC20) hosted by the International Association for the Study of Lung Cancer (IASLC) taking place virtually January 28-31, 2021. Spectrum has a late-stage pipeline with novel assets that serve areas of unmet need.

Pharmaceuticals 52

Pharmaceuticals Clinical Trials Licensing Licensing 52

The Pharma Data

DECEMBER 13, 2020

Our highly experienced teams in Singapore and the US span antibody discovery, pharmacology, production and clinical development. Together we aim to accelerate the journey of new drugs from concept to clinical care. 2020; 19: 490–501. [3] SINGAPORE , Dec. Mol Cancer Ther. Cancer Res. 2018; 78: 3645–3658.

Clinical Development 52

Clinical Development Clinical Trials Therapies Trials 52

The Pharma Data

DECEMBER 17, 2020

The trial remains on-track to complete enrollment of all 500 patients in the United States and Australia before the end of 2020, despite the worsening of the COVID-19 pandemic. In its Phase II clinical trial, TLC599 significantly reduced pain at and through every scheduled visit through six months. SOUTH SAN FRANCISCO, Calif.

Clinical Trials 40

Clinical Trials Trials Pharmaceutical Companies Clinical Pharmacology 40

The Pharma Data

OCTOBER 21, 2020

22, 2020 /PRNewswire/ — Synlogic, Inc. 22-25, 2020. 22-25, 2020. Title: Development of a Synthetic Biotic, SYNB8802, for the Treatment of Enteric Hyperoxaluria Poster #: PO0650. CAMBRIDGE, Mass. ,

Engineering 40

Engineering Clinical Trials Clinical Development Treatment 40

The Pharma Data

NOVEMBER 11, 2020

12, 2020 (GLOBE NEWSWIRE) — Inozyme Pharma, Inc. Separately, Fast Track Designation facilitates the potential expedited development and review of a drug for the treatment of a serious or life-threatening disease and that has demonstrated the potential to address unmet medical needs. Third Quarter 2020 Financial Results.

Clinical Trials 40

Clinical Trials Trials Disease FDA 40

The Pharma Data

NOVEMBER 10, 2020

The NCT03763149 study is a phase 1a clinical study evaluating the tolerability, safety, and PK/PD properties of IBI188 (letaplimab) as monotherapy for advanced malignancies that failed in standard treatments. . SAN FRANCISCO , U.S. and SUZHOU, China , Nov.

Clinical Trials 52

Clinical Trials Treatment Trials Disease 52

The Pharma Data

DECEMBER 15, 2020

16, 2020 02:47 UTC. Nasdaq: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced the pricing of an underwritten public offering of 3,725,000 shares of its common stock at a public offering price of $21.50

FDA Approval 40

FDA Approval Disease Therapies Clinical Development 40

The Pharma Data

OCTOBER 29, 2020

Biotechs get scalable early to late phase clinical offering from Cromos Pharma and Avance Clinical collaboration in Australia and Europe. Clinical Development Strategy – we provide expert guidance on study design, favorable venues, local and global landscape to improve study outcomes.

Clinical Trials 40

Clinical Trials Trials International Biosimilars 40

The Pharma Data

SEPTEMBER 16, 2020

New integrated analyses from our tumour agnostic Rozlytrek ® (entrectinib) clinical development programme. Roche highlights featured at ESMO Virtual Congress 2020. Overview of key presentations featuring Roche medicines at ESMO 2020. Join this event on Roche’s LinkedIn page here. Abstract title. Abstract number.

Trials 52

Trials Treatment Disease Pharmaceuticals 52

The Pharma Data

OCTOBER 29, 2020

30, 2020 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today new data for baricitinib (marketed as OLUMIANT ® ) will be presented at the annual Fall Clinical Dermatology meeting taking place virtually October 29-November 1, 2020. vice president of immunology development at Lilly.

Therapies 52

Therapies Treatment Disease Clinical Trials 52

The Pharma Data

JANUARY 4, 2021

The most recent data from the Surveillance, Epidemiology, and End Results Program (SEER) of the US National Cancer Institute (NCI) estimated 19,940 new cases of AML and 11,180 deaths from this disease in the United States in 2020. ” Reference. 1. DeSantis CE, Lin CC, Mariotto AB, et al.

FDA 40

FDA Therapies Drugs Treatment 40

The Pharma Data

NOVEMBER 18, 2021

Gilead has been encouraged by early clinical data generated for each of the three programs. By concluding in early to all three programs now, Gilead and Arcus are suitable to accelerate the clinical development and advancement of these clinical- stage motes and grease the disquisition of treatment combinations across the portfolios.

Research 52

Research Clinical Development Small Molecule Packaging 52

The Pharma Data

DECEMBER 10, 2020

GREEN BROOK, NJ, December 10, 2020 /24-7PressRelease/ — Gianluca Pirozzi, MD, PhD, has been included in Marquis Who’s Who. He became Head of Development for Rare Diseases and Gene Therapy in Sanofi-Genzyme’s office in Cambridge, Massachusetts. positions he assumed in 2020.

Disease 52

Disease Research Doctors Clinical Development 52

The Pharma Data

SEPTEMBER 19, 2020

Basel, 19 September 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that it presented the latest results from three Phase III studies from the Tecentriq® (atezolizumab) clinical development programme in triple-negative breast cancer (TNBC) at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.

Treatment 52

Treatment Disease Therapies Pharmaceuticals 52

The Pharma Data

DECEMBER 23, 2020

The Company has Now Resumed the Clinical Development of its Proposed Anti-Nausea Pharmaceutical Grade Version of Tauri-Gum. 24, 2020 (GLOBE NEWSWIRE) — via NewMediaWire — Tauriga Sciences Inc. On December 18, 2020 – The Company issued the following press release: “Tauriga Sciences Inc. NEW YORK, NY, Dec.

Science 52

Science Pharmaceuticals Clinical Development Production 52

Vial

APRIL 10, 2024

With over 1,100 CROs worldwide as of 2020, choosing the appropriate partner often requires evaluating the advantages and disadvantages of large global CROs versus mid/small ones. Still in its early stages, Vial was established in 2020 and has quickly emerged as a leading CRO. increase on a reported basis and an 4.8%

Clinical Trials 52

Clinical Trials Trials Clinical Research Compliance 52

The Pharma Data

JANUARY 5, 2021

COVID-19 have caused delays to submission and processing of the regulatory application to initiate clinical development in China. Due to the unforeseen delays, Targovax has extended the term of IOvaxis’s license option by 3 months, otherwise the agreement remains unchanged. OSLO, Norway , Jan.

Licensing 40

Licensing Licensing Vaccine Clinical Development 40

The Pharma Data

DECEMBER 28, 2020

29, 2020 /PRNewswire/ — Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that the company has appointed Dr Christina Reimer as Chief Medical Officer. Her international experience in leading clinical development and in building development organizations will significantly strengthen our clinical capacity.

Clinical Development 52

Clinical Development Doctors Drug Development International 52